

# A multicenter, prospective, randomized study protocol to demonstrate the superiority of a bone-anchored prosthesis for anular closure used in conjunction with limited discectomy to limited discectomy alone for primary lumbar disc herniation

**International Journal of Clinical Trials 2016; 3(3): 120-131.**

**doi:** <http://dx.doi.org/10.18203/2349-3259.ijct20162794>.

PD Klassen, R Hes, GJ Bouma, S Eustacchio, M Barth, A Kuršumović, S Jadik, V Heidecke, R Bostelmann, C Thomé, P Vajkoczy, H-P Köhler, J Fandino, R Assaker, E Van de Kelft, S Fröhlich, W van den Brink, J Perrin, J Wolfs, M Arts, F Martens

## Abstract

**Background:** Same-level reherniation and progressive degeneration with disc height loss are main causes of poor outcome after discectomy and may necessitate reoperation. A novel prosthesis for anular closure was developed to address these causes.

**Methods:** The design of a multicenter, prospective, randomized, post-market superiority trial comparing limited lumbar discectomy augmented with this device (intervention group) with limited lumbar discectomy alone (control group) is presented.

**Results:** Patients with single-level (L1-S1) posterior or posterolateral disc herniation and radiologic confirmation of neural compression for whom at least six weeks of conservative treatment has failed are eligible. Patients must have posterior disc height  $\geq 5$  mm at index level and baseline Oswestry and VAS leg pain scores of  $\geq 40/100$ . Intraoperatively, subjects meeting anular defect size criteria post-discectomy (4-6 mm tall and 6-10 mm wide) will be randomized to study groups in a 1:1 ratio using centralized, web-based software. A Bayesian statistical approach will be used to enroll 400 to 800 subjects who will be followed for at least 24 months. Two co-primary endpoints will be assessed at 24 months: 1) a composite of leg pain, clinical function, disc height maintenance, and absence of reherniation, reoperation, and device failure; and 2) absence of reherniation based upon independent radiologic analysis.

**Conclusions:** This type of analysis is becoming increasingly important as governments and health insurers continue to be pressured to spend limited healthcare funding wisely.

This article contains off-label use information. Please use medical discretion when reviewing this article.

**Barricaid is approved for the following indications for use:**

Reducing the incidence of reherniation and reoperation in skeletally mature patients with radiculopathy (with or without back pain) attributed to a posterior or posterolateral herniation, and confirmed by history, physical examination and imaging studies which demonstrate neural compression using MRI to treat a large anular defect (between 4-6 mm tall and between 6-10 mm wide) following a primary discectomy procedure (excision of herniated intervertebral disc) at a single level between L4 and S1.

**Financial disclosure:**

One or more authors have received financial compensation from Intrinsic Therapeutics. Full financial disclosures can be found in the respective manuscript.

**WARNING:** This product has labeling limitations. See package insert for additional warnings, precautions and possible adverse effects.

**CAUTION:** USA law restricts this device to sale by or on the order of physician. All medical devices have associated risks. Please refer to the package insert and other labeling for a complete list of indications, contraindications, precautions and warnings ([www.barricaid.com/us-en/instructions](http://www.barricaid.com/us-en/instructions)). For further information on Barricaid, contact your Intrinsic representative.